Latest: FDA Approves New Biosimilar for Oncology Treatment

Praxis’ Vormatrigine Shows Significant Ability to Reduce Seizure Incidence in Phase 2 RADIANT Study

0 Mins
New study reveals vormatrigine significantly reduces focal onset seizures, offering hope for improved epilepsy treatments at the upcoming International Epilepsy Congress.
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago